What is it about?
This paper reports the findings from a study of the ACE2 enzyme activity from the blood samples of about 50 stroke patients at the University of Florida. It describes how the activity of ACE2 is initially decreased when patients first arrive to the hospital with an acute ischemic stroke, and then a few days later it returns to baseline levels.
Featured Image
Why is it important?
This gives some promising evidence that the changes observed in animal models of stroke are a good representation of what is happening in humans, and there is the potential that treatments that target the activity of this enzyme or its downstream receptors may improve outcomes in treating ischemic stroke.
Perspectives
Having conducted years of preclinical work in the field of stroke neuroprotection, I am especially encouraged by these data in humans which solidify ACE2 and the neuroprotective ACE2-Ang-(1-7)-Mas axis as a promising clinical target for drugs under study in animal models.
Douglas Bennion
University of Iowa Hospitals and Clinics
Read the Original
This page is a summary of: Serum activity of angiotensin converting enzyme 2 is decreased in patients with acute ischemic stroke, Journal of the Renin-Angiotensin-Aldosterone System, August 2016, SAGE Publications,
DOI: 10.1177/1470320316661060.
You can read the full text:
Contributors
The following have contributed to this page
